MT-101 – AKI, CKD
MT-101 as a Tie2-activating mAb for treating renal diseases (AKI, CKD)
First-in-class Tie2 agonist antibody
A fully humanized antibody that combines direct Tie2 activation with Ang-2 inhibition
Disease-modifying mechanism
Restores renal microvasculature to suppress inflammation and fibrosis → improve kidney function
High unmet need
CKD affects ~9% of adults worldwide (~700M patients) with no therapies that halt progression;
AKI also carries high morbidity and mortality with no effective standard of care
Commercial value
As the first antibody directly targeting the Ang/Tie2 axis, MT-101 covers a broad patient population from AKI to CKD,
with distinct clinical and commercial potential